Objective: The aim of this study was to examine the effect of conjugated equine estrogens alone (ET), conjugated equine estrogens + medroxyprogesterone (EPT), calcitriol alone, calcitriol + EPT/ET, or placebo on serum lipid profile and analyze the interaction with estrogen receptor-> gene single nucleotide polymorphisms (ESR-> SNPs) on the response to therapy.
C ardiovascular disease (CVD) is the leading cause of mortality in both men and women in the United States and other developed countries. However, the incidence of the disease is delayed in women by about a decade, probably as a consequence of a protective effect of estrogen before menopause. 1<3 The risk of CVD in women increases markedly after menopause. 4, 5 Several lines of evidence indicated that the unfavorable lipid-lipoprotein changes seen after menopause were related to lack of estrogen and had led to the suggestion that hormone therapy (HT) might reduce the risk of CVD.
A number of observational studies reported a lower risk of CVD in women taking estrogen. A meta-analysis of more than 30 observational studies showed a 56% reduction in the risk of a major coronary event in healthy current estrogen users compared with women who have never used estrogen. 6, 7 The cardioprotective effect of estrogen therapy (ET) has been attributed to a number of potential mechanisms, of which favorable changes in lipid-lipoprotein profile are estimated to contribute to at least one third of the cardioprotective effect. 8 Observational studies and clinical trials that evaluated the effect of exogenous estrogen on cardiovascular risk have demonstrated favorable changes in serum lipid and lipoprotein levels, including a decrease in serum levels of the total cholesterol and low-density lipoprotein (LDL) and increased serum highdensity lipoprotein (HDL) and triglyceride levels. 8<13 However, other factors including route, type, and dose of estrogen administration and the coadministration of a progestin affect the response of serum lipids. 11<19 Medroxyprogesterone acetate (MPA) is the most commonly used progestogen in HT regimens in the United States for women with an intact uterus to reduce the increased incidence of endometrial cancer that accompanies unopposed estrogen use. MPA was reported to attenuate the beneficial effects of estrogen on the cardiovascular system in a postmenopausal estrogen progestin intervention trial 11, 20 and also by other investigators. 21 Debate is continuing on whether there is an impact of the added progestins on the beneficial effects of estradiol on the cardiovascular system. 22, 23 Also, studies in the cynomolgus macaque had previously indicated an attenuation of ET effects by MPA on the development of atherosclerotic plaque, as well as coronary artery reactivity. 24<27 However, observational studies of HT reported no differences in the risk for clinical cardiovascular events between users of estrogen alone and users of estrogen + progestins, including women using predominantly MPA. 18, 19, 28 In two large randomized clinical trials, the Heart and Estrogen/ Progestin Replacement Study and the Estrogen Replacement and Atherosclerosis Study, which examined the use of HT in postmenopausal women with established coronary heart disease (CHD), no beneficial effect of HT in reducing the CHD risk was found. 29, 30 Subsequently, the results from the Women's Health Initiative (WHI) were published; WHI is a large, randomized trial that reported that women taking estrogen in combination with progestin had an increased incidence of CHD compared with placebo. 31 The biological rationale for the beneficial effect of ET is that estrogen increases the hepatic synthesis of LDL receptor (apolipoprotein B-100), resulting in increased LDL uptake and, therefore, decreased circulating LDL levels. 32 It also increases the activity of the enzyme lipoprotein lipase, thus raising HDL levels. 33 Although the positive role of ET treatment on serum lipids is well known, the influence of HT on lipid parameters is still controversial.
Most of the biological actions of estrogen are exerted through estrogen receptors (ERs) that belong to the family of ligand-gated nuclear transcription factors. 34, 35 There are two types of ERsV> and A. ER> is considered to be the main receptor for estrogen. There are various single nucleotide polymorphisms (SNPs) present in ER>VPvuII and XbaI. These are present in intron 1 of the ER> gene ( Fig. 1 ). PvuII is present, with j397 base pairs (bp), from exon 2 and produces a C to T transition. 36 XbaI is present, with j351 bp, from exon 2 and produces an A to G transition. 37 These SNPs have previously been shown to be associated with bone markers, 38 bone mineral density and fractures, 39, 40 and CVD including myocardial infarction (MI) 41, 42 and stroke. 43 Few studies have examined the association of change in serum lipids in response to HT with ER> gene SNPs. 37, 44, 45 In a randomized, double-blinded clinical trial, we examined the effect of conjugated equine estrogens alone (ET; in women who underwent hysterectomy) or in combination with medroxyprogesterone (EPT; in women with an intact uterus) on lipid profile in older postmenopausal women and further analyzed the impact of ER> gene SNPs on the response to therapy.
METHODS
Four hundred eighty-nine older women aged 65 to 77 years were recruited to participate in a 3-year double-blind, placebocontrolled clinical trial, Sites Testing Osteoporosis Prevention or Intervention Treatment. The study was originally designed to test the effects of estrogen in women without a uterus (ET); estrogen + MPA in women with a uterus (EPT); calcitriol; and the combination of ET/EPT and calcitriol; on bone density, biochemical markers of bone remodeling, falls, and fractures, compared with placebo. The women were recruited into the study through advertisements in local newspapers or by mass mailing of letters inviting them to participate in a 3-year study. Women were excluded if they had severe chronic illness, had primary hyperparathyroidism or active renal stone disease, and had taken medications, such as bisphosphonates, anticonvulsants, estrogen, fluoride, or thiazide diuretics in the previous 6 months. Additional inclusion criteria were normal liver and kidney function. All participants were free living, in good health, and ambulatory. Of the 489 women, 470 were white, 13 were black, 4 were Hispanic, 1 was Asian, and 1 was of mixed race. Creighton University's institutional review board approved the study, and all participants signed an informed consent form to participate in the study.
Women were randomly assigned to either conjugated equine estrogens (Premarin) 0.625 mg daily + MPA (Provera) 2.5 mg daily (EPT); calcitriol (Rocaltrol) 0.25 Kg BID; the combination of Premarin + Provera + calcitriol; or matching placebos; hysterectomized women (n = 290) assigned to estrogen were not given the progestin (ET). The detailed study design is depicted in Figure 2 . Details about the safety assessment and study compliance have been published elsewhere. 46 Dietary intake at baseline and at the end of the study (36 mo) was assessed using 7-day food diaries. A dietitian asked the women to complete a 7-day food dairy and nutrient supplement record. Plastic food models (NASCO, Fort Artinson, WI) were used to help participants to better estimate the quantities consumed. The average daily caffeine and calcium intakes were calculated using the Food Processor II Plus nutrition and diet analysis system (version 5.1; Esha Research, Salem, OR).
On entry into the study, women underwent a physical examination, and a detailed medical history was obtained from a questionnaire. At baseline recruitment and at 36 months, participants were also provided with a questionnaire to report their smoking and alcohol history, reproductive history, and present use of medications, vitamins, and mineral supplements. Current smokers were considered as smokers, whereas past smokers and women who never smoked were classified as nonsmokers. Alcohol use was stratified into drinkers and nondrinkers.
At baseline and at the end of the study, a fasting blood sample was collected from each participant between 0700 and 0900 hours for the measurement of serum total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol levels. Serum total cholesterol, triglycerides, and HDL cholesterol were estimated using an autoanalyzer (Vitros 750 and Vitros 950 chemistry analyzer; Ortho-Clinical Diagnostics, Raritan, NY). The method used for total cholesterol measurement is based on an enzymatic method proposed by Allain et al. 47 Triglyceride analysis is based on an enzymatic method described by Spayd et al. 48 HDL cholesterol is estimated after pretreatment of the sample to precipitate LDL and very lowdensity lipoprotein (VLDL). VLDL cholesterol level is calculated as triglyceride/5. LDL cholesterol is calculated as [total cholesterol j (HDL + VLDL)].
ER genotype analysis
Genomic DNA was isolated from peripheral white blood cells using the Puregene kit (Gentra systems). The samples were genotyped for PvuII (rs2234693) and XbaI (rs9340799) restriction fragment length polymorphisms (RFLPs) as has been published by us previously. 38 Briefly, the oligonucleotide primers used included forward, 5 ¶-CTGCCACCCTAT CTGTATCTTT-3 ¶ and reverse, 5 ¶-ACCCTGGCGTCGATT ATCTGA-3 ¶. Conventional polymerase chain reaction was performed for 30 cycles under the following conditions: denaturation at 94-C for 60 seconds annealing, at 50-C for 60 seconds, and extension at 72-C for 90 seconds. The polymerase chain reaction products (È1.3-kbp-long fragments) were digested with restriction endonuclease enzymesVPvuII and XbaI. The resulting fragments were separated by gel electrophoresis on 2% agarose gel stained with ethidium bromide and visualized on a transilluminator under UV light and were photographed. These were coded as P/p (PvuII) and X/x (XbaI), with uppercase letters signifying the absence and lowercase letters signifying the presence of restriction sites, respectively.
Statistical analysis
Data were analyzed using SAS package (version 8.2). The following procedures were performed for both the intent-totreat and adherent-to-treatment groups. In each case, the baseline characteristics between the six treatment groups were compared using a one-way analysis of variance (ANOVA), and the averages and standard errors were computed. The percentage of smokers and alcohol drinkers by treatment group and their standard errors were also analyzed using the W 2 test. The unadjusted (crude means) baseline lipid variables and the unadjusted percent change over baseline lipid parameters of the six treatment groups were compared again using the one-way ANOVA. When the treatment effect was significant at the 0.05 level in the ANOVA models, multiple comparisons of the least squares means by treatment were performed using the Tukey method. In addition to these Bcrude[ means, in an analysis of covariance (ANCOVA) model, the treatment effects on (1) the baseline values and (2) the percent change from the baseline in the variables of interest were assessed. The effects of the covariates, age weight, height, body mass index (BMI), dietary calorie intake, fiber intake, calcium intake, caffeine intake, alcohol status, smoking status, and age at menopause were adjusted for in these analyses. When the percent change was the outcome variable, the corresponding baseline value was also used for the adjustment. The least squares means (ie, the adjusted means) were computed by the MIXED procedure of SAS (version 8.2). When the treatment effects were significant at the 0.05 level in the ANCOVA models, multiple comparisons of the least squares means by treatment were performed using the Tukey method. The impact of RFLP on the treatment response of serum lipids was assessed by the ANCOVA models after adjustment for the above-mentioned confounders + statin users and the baseline serum lipid for each of the corresponding values; for example, in the analysis of the final serum cholesterol at 36 months, baseline serum cholesterol was used as a covariate in the analysis in addition to the above-mentioned covariates. When the treatment effects were significant at 0.05 level in the ANCOVA models, multiple comparisons of the least squares means by treatment were performed using the Bonferroni adjustment.
RESULTS
Of the 489 women enrolled into the study, 416 women came for the final visit (36 mo), of which 337 women were adherent to treatment (980% compliant with study medication). The data of the 416 women were included for the intent-to-treat analysis. Of these, one woman with suspected Paget's disease was excluded from the analyses, and three women had no lipid profile data available. Hence, the final intent-to-treat analyses were performed on the data of 412 women. The data of the 337 women who were adherent to the treatment regimen were used for complier analyses (980% compliance with study medication). The initial randomization of women into different treatment groups is depicted in Figure 2 .
In both intent-to-treat and complier analyses, there were no significant differences between the treatment groups with regard to their age, height, weight, BMI, dietary calcium, and caffeine intake ( Table 1 ). The distribution of smokers and alcohol drinkers was also not different between the six treatment groups ( Table 1) .
Intent-to-treat cross-sectional analysis
At baseline, there were no significant differences in the means of serum cholesterol and HDL cholesterol between any of the treatment groups ( Table 2 ). The unadjusted means for serum triglycerides and serum VLDL were significantly lower in the women assigned to the EPT + calcitriol treatment regimen compared with the women assigned to ET treatment (123.4 T 7.7 vs 180.7 T 15.0 [P G 0.01] and 24.7 T 1.5 vs 34.8 T 2.7 [P G 0.05], respectively; Table 2 ); however, after adjustment for differences in clinical characteristics and dietary factors, the changes became nonsignificant (adjusted means for serum triglycerides were 124.6 T 11.5 mg/dL in the EPT + calcitriol group vs 174.2 T 13.3 in the ET group [P 9 0.05], and for serum VLDL, adjusted means were 24.4 T 2.1 vs 33.0 T 2.5 [P 9 0.05], respectively). The adjusted means for serum LDL cholesterol were significantly higher in the women receiving the EPT treatment at baseline compared with the women receiving the calcitriol (145.8 T 4.6 in EPT group vs 128.5 T 4.0 in calcitriol group; P G 0.05). The unadjusted ratio of the mean LDL/HDL cholesterol level in the EPT group was significantly greater compared with that in the calcitriol group (3.15 T 0.15 vs 2.65 T 0.08; P G 0.05) and was similar in the adjusted analysis (3.05 T 0.13 vs 2.49 T 0.11 [P G 0.01], respectively). The unadjusted LDL/ HDL cholesterol level was also significantly higher in the women in the ET group compared with the women in the calcitriol group (3.20 T 0.19 vs 2.65 T 0.08 [P G 0.05], respectively; Table 2 ). Also, the mean LDL/HDL ratio in the EPT + calcitriol group was significantly different from the EPT group (both adjusted and unadjusted; Table 2 ).
Compliers analysis
At baseline, there were no significant differences in unadjusted and adjusted means between the six treatment groups with regard to serum cholesterol, triglycerides, HDL cholesterol, and VLDL cholesterol ( Table 2) , but there was a significant difference in baseline adjusted serum LDL cholesterol between the women assigned to EPT and calcitriol treatment regimens (154.9 T 5.4 vs 132.9 
Longitudinal analysis Intent to treat
Serum total cholesterol. The results of unadjusted analysis are presented in Table 3 . The decrease in total cholesterol in Table 3 ); however, it became nonsignificant after the adjustment for relevant confounders (Fig. 3) .
Serum triglycerides. The increase in serum triglycerides was significantly higher in the women receiving ET + calcitriol compared with placebo (41.6 T 10.7 vs 10.5 T 6.0 mg/dL; P G 0.05; Table 3 ); the adjusted increase was significantly higher in the EPT and ET + calcitriol groups compared with placebo and EPT + calcitriol (only EPT group) groups Table 3 ). For adjusted analysis, serum HDL increased by 13.9% T 2.5% in the EPT group, 13.1% T 2.9% in the ET group, 12.7% T 2.5% in the EPT + calcitriol group, and 15.6% T 3.2% in the ET + calcitriol group vs 2.66% T 2.1% The values are means T SE in mg/dL. Comparison between the treatment groups was done using either the analysis of variance (for crude means) or analysis of covariance (for adjusted means; adjusted for age, weight, and BMI dietary factors). Post hoc significance was computed by the Tukey multiple comparison method. in placebo (P G 0.05) and decreased in the calcitriol-only group (j0.1% T 2.2%; P G 0.05; Fig. 4 ).
Serum LDL. There was a significantly greater decrease in serum LDL in all of the hormone treatment groups as compared with the placebo and calcitriol groups, both unadjusted and after adjustment for confounders (unadjusted change was j25 T 4.2, j26.3 T 4.7, j11.5 T 3.5, and j19.9 T 5.5 mg/dL in EPT, ET, EPT + calcitriol, and ET + calcitriol groups vs j1.3 T 2.1 and j0.84 T 2.3 in placebo and calcitriol groups, respectively [P G 0.05]; Table 3 ). For adjusted analysis, serum LDL decreased in the EPT (j13% T 2.6%), ET (j15.5% T 3%), EPT + calcitriol (j7.2% T 2.5%), and ET + calcitriol groups (j14.2% T 3.2%) vs 0.3% T 2.1% increase in the placebo group (P G 0.05) and 1.1% T 2.2% increase in the calcitriol-only group (P G0.05; Fig. 4 ). The exception was the adjusted and unadjusted percent change in LDL cholesterol in the EPT + calcitriol group, which was not significantly different.
Serum LDL/HDL ratio. The adjusted and unadjusted serum LDL/HDL ratio was also significantly lowered in all the four treatment groups receiving the hormones compared with that of the placebo and calcitriol groups (unadjusted change was j0.84 T 0.12, j0.82 T 0.11, j0.41 T 0.09, and j0.68 T 0.13 in EPT, ET, EPT + calcitriol, and ET + calcitriol groups vs j0.05 T 0.06 and 0.05 T 0.05 in placebo and calcitriol-only groups; respectively [P G 0.05]; Table 3 ). For adjusted analysis, the results were similar: j21.1% T 3.3% in the EPT group, j22.3% T 3.9% in the ET group, j14% T 3.3% in the EPT + calcitriol group, and j22.5% T 4.1% in the ET + calcitriol groups vs 0.35% T 2.7% and 4.7% T 2.8% in the placebo and calcitriol groups; respectively [P G 0.05]; Fig. 4) .
Serum VLDL. The unadjusted serum VLDL of the women receiving the ET + calcitriol treatment increased significantly more than placebo (8.3 T 2.1 mg/dL increase in ET + calcitriol vs 2.7 T 1.0 in placebo [P G 0.05]; Table 3 ). However, the adjusted percent change in VLDL levels was significantly higher in women in the ET + calcitriol group compared with the women belonging to the placebo, calcitriol, and EPT + calcitriol treatment groups (40% T 6.6% in ET + calcitriol group vs 13.7% T 4.4%, 15.8% T 4.6%, and 13.6% T 5.3% in placebo, calcitriol, and EPT + calcitriol groups, respectively [P G 0.05]; Fig. 4 ).
Complier analysis
There were no major differences from the intent-to-treat analysis for serum total cholesterol, serum HDL, serum LDL, LDL/HDL ratio, and serum VLDL (Table 3; Table 3 ). For adjusted analysis, change in serum triglycerides was 46.5% T 6.8% in the EPT and 42.7% T 7.8% in the ET + calcitriol groups vs 12.8% T 5.1% in the placebo and 16.4% T 5.4% in the calcitriol groups, respectively (P G 0.05; Fig. 5 ).
Effect of estrogen genotypes
ER> gene RFLPs were done in 324 women for both PvuII and XbaI. These were in apparent linkage disequilibrium, and the distribution did not differ from that expected under Hardy-Weinberg equilibrium. There were no significant differences in baseline serum lipids according to genotypes.
There was a significant association between PvuII RFLP and the response to treatment for serum cholesterol and VLDL. Genotypes containing the p allele had a greater decrease in serum cholesterol (j19 mg/dL in pp vs 7 mg/dL in Pp; P = 0.06) and an increase in serum VLDL (13.3 mg/dL in pp vs j5 mg/dL in PP; P = 0.0006) compared with those having the P allele in the ET + calcitriol group (Table 4 ). For serum triglycerides and serum LDL, there was a trend (overall P value G 0.05) for greater decrease in the genotypes containing the p allele in the ET + calcitriol group (j66.8 mg/dL in pp vs j25.8 mg/dL in PP for serum triglycerides and j40.4 mg/dL in pp vs j19.5 mg/dL in PP for serum LDL; Table 4 ).
XbaI RFLP also showed a significant association in the response to treatment for serum cholesterol and serum LDL. Genotypes including the x allele had a greater decrease in serum cholesterol in the EPT + calcitriol group at the end of 3 years compared with the X allele alone (j8.9 mg/dL in Xx vs 36.8 mg/dL in XX; P = 0.03) and a greater decrease in serum LDL in the ET + calcitriol group (j40.4 mg/dL in xx vs 9.2 mg/dL in Xx; P = 0.01; Table 4 ). For serum VLDL, h there was a trend (overall P value G 0.05) for greater increase in xx versus XX (13.3 mg/dL vs j2.5 mg/dL, respectively). There were no significant differences in other serum lipids for the response to treatment according to genotypes.
DISCUSSION
The results of this study show that HT (estrogen with or without MPA) favorably lowers serum LDL and increases serum HDL but also increases serum triglycerides in healthy older postmenopausal women and further indicate that the effect of treatment (HT and/or calcitriol) is modified by ER SNPs. This is the first study of its kind looking at the interaction between ER SNPs, HT, calcitriol, and treatment response of serum lipids in a longitudinal follow-up.
The positive effects of ET on serum lipids have been reported in previous studies. In a randomized, double-blind trial in younger postmenopausal women, treatment with ET resulted in a significant dose-dependent reduction in LDL cholesterol and an increase in serum HDL over the dose range 0.3 to 0.625 mg/day. At all three doses of ET studied (0.3, 0.45, and 0.65 mg/d), LDL cholesterol was significantly reduced, and HDL was increased relative to both baseline and placebo treatment. 49 In addition, there were favorable effects on hemostatic factors including fibrinogen and plasminogen activator inhibitor-1. Similar findings were reported in another randomized, double-blind, crossover trial. 50 There has been interest in the cardiovascular effect profile of HT in postmenopausal women. At the center of debate are two large studies, one observational (Nurses Health Study [NHS] ) and the other a randomized controlled trial (WHI). 31, 51 NHS was a large observational study involving 121,700 female nurses aged 30 to 55 years at the time of enrollment in 1976. 18, 52 In the latest analysis involving 70,533 postmenopausal women with no previous CVD followed for up to 20 years, there was a significant reduction in major CHD (nonfatal MI and coronary death) after adjustment for age, BMI, history of diabetes, hypertension, high cholesterol level, age at menopause, smoking status, and parental history of premature heart disease (relative risk [RR], 0.61 [95% confidence limit (CL), 0.52-0.71], for current users, and RR, 0.82 [CL, 0.72-0.94], for past users of HT). There was a small difference in risk reduction based on the type of HT (RR, 0.55 [CL, 0.45-0.68], for women taking oral conjugated estrogens alone, and RR, 0.64 [CL, 0.49-0.85], for women taking estrogen + progestin). 52 However, the initial results of the WHI trial showed that estrogen + progestin therapy increased the risk of CHD (nonfatal MI and CHD death), stroke, and venous thromboembolism (VTE). 31 These results were later modified based on more data, and after central adjudication, estrogen + progestin therapy still significantly increased the risk of CHD (hazard ratio, 1.24; nominal 95% CI, 1.00-1.54; adjusted CI, 0.97-1.60) and stroke (hazard ratio, 1.31; nominal 95% CI, 1.02-1.68; adjusted CI, 0.93-1.84). 53 The absolute risk was still very lowVthe findings suggest that at 1 year, 1 per 1,600 user women taking EPT compared with placebo developed six more CHD events. There was no increase in the CHD death or overall mortality, congestive heart failure, and a composite of CHD, revascularization, or angina. Therefore, although the risk for MI increased, the risk for angina was not increased. However, there were other adverse events (invasive breast cancers, strokes, VTEs, and pulmonary embolisms) and benefits (less colorectal cancers, hip fractures, and total fractures that increased the risk benefit of HT). In the ET arm of the WHI trial, there was no significant effect on CHD, although the risk of stroke and VTEs was elevated; however, none of the cardiovascular events were significant after adjustment. 51 There was no increase in breast cancer on ET.
In a subgroup analysis to determine specific populations at increased risk of CHD, no significant interaction between age or years since menopause and treatment was observed (P = 0.36 for the age analysis and P = 0.33 for years-sincemenopause analysis), although there was a numerical trend toward a higher risk with EPT more years after menopause. 53 Although the tests for interaction were nonsignificant, women not using statins or aspirin (Q80 mg/d) were at increased risk of CHD. In addition, women with baseline serum LDL cholesterol levels (9155 mg/dL) had an increased risk of CHD when started on EPT compared with those with lower LDL cholesterol. Age was also a determinant of CHD risk. The average age of women starting HT was 63 years. BMI was also a possible risk because the average BMI was 28.5 kg/m 2 . 53 In NHS, the risk of CHD increased with increasing BMI; the risk was increased 356% in women with a BMI of 29 kg/m 2 or greater compared with women with a BMI of less than 21 kg/m 2 . 54 In a randomized, double-blind trial involving 222 postmenopausal women 45 years or older without preexisting CVD and with a serum LDL of 130 mg/dL or greater, the average rate of progression of subclinical atherosclerosis measured by change in intimal-media thickness of the right distal common carotid artery was slower in women taking ET with 17A-estradiol than in women taking placebo. 55 However, the results of other studies are less convincing. 30 These apparent differences in observational and intervention studies could be partly explained by the findings of various animal studies carried out by Clarkson 56 and others. 57 Specifically, these studies demonstrated that the extent of subclinical atherosclerosis at baseline seems to be a significant modulator of the atheroprotective effects of HT and that estrogen inhibits the initiation of fatty streaks in vasculature but does not inhibit the progression of established lesions. This Btiming hypothesis[ might play an important role in determining the effects of ET in various populations. In a meta-analysis of 30 trials of HT involving 26,708 women with a mean follow-up of 4.5 years, hormone therapy reduced mortality in the younger age group (G60 y; odds ratio, 0.61; CI, 0.39-0.95) but not in the older age group (960 y; odds ratio, 1.03; CI, 0.90-1.18). 58 ER SNPs seem to affect the response of serum lipids to HT treatment. The genotypes that included the x and p alleles showed significantly greater response of serum cholesterol, serum LDL, and serum VLDL compared with the X and P alleles, respectively. We have shown previously from the same data set that PvuII and XbaI SNPs interact with the treatment response to HT of bone loss measured by changes in bone mineral density and bone markers. 38 Only a few studies have looked at the interaction between ER> genotypes and the response in serum lipids to HT. In fact, the first study done by Herrington et al 37 found a significant association between PvuII SNPs and treatment response to HT for serum HDL with a greater increase in serum HDL in women with the PP genotype as compared with Pp or pp. Other small studies have found similar results. 44, 45 The mechanism by which ER> SNPs lead to changes in serum lipids is not clear. Initial reports had suggested an alteration in protein expression secondary to changes in the messenger RNA splicing of PvuII gene. 59 Because these are present in the noncoding region (activation domain) of the gene, the structure of receptor protein should not be altered. Instead, there is growing evidence that these SNPs affect the binding of transcription factors like myb to the ER> gene, leading to decreased expression of the ER> receptor. Herrington et al 60 found that the presence of the P allele resulted in a more than 10-fold increase in a downstream reporter activity as compared with only a 2.5-fold increase in an activity with the p allele; both sets of genes were stimulated by transcription factor myb. However, whether these SNPs affect the quality or quantity of ER> gene messenger RNA transcripts or protein expression remains to be established. Schuit et al 61 demonstrated that these SNPs (p and x alleles) are associated with lower serum estradiol levels in postmenopausal women. They hypothesized that these SNPs affected the expression of one of the subtypes of 17A-hydroxysteroid dehydrogenase enzyme that catalyzes the transformation of estrone into estradiol. It might also be possible that these SNPs are in linkage disequilibrium with another SNP in the ER> gene that affects the expression of ER>.
In a prospective study involving 1,739 men and women from the Framingham cohort followed for 27 years, the investigators found a significant association between ER> SNPs and MI risk with three times greater risk of MI (95% CI, 1.7-5.2) in men with the PP genotype as compared with Pp or pp. 41 Similar results were found for stroke in 2,709 male participants of the Second Northwick Park Heart Study, with an increased risk in the PP genotype independent of established cardiovascular risk factors including diabetes. 43 In an autopsy study from Finland, the investigators found that men 53 years or older with the P/p and P/P genotype had twofold to fivefold larger complicated lesions and odds ratio of 6.2 and 10.6, respectively, for coronary thrombosis than did men with the p/p genotype after adjustment for age and BMI. 62 As noted, all these studies found worse cardiovascular outcomes in men associated with the P allele. In contrast, the results of the Rotterdam Study in 3,791 postmenopausal women followed for 8 to 10 years suggested that the p and x alleles were associated with an increased MI risk. 42 These apparent opposing results in men and women can be explained by the fact that there is no cessation of hypothalamic-pituitary axis in men leading to sufficiently high serum estradiol levels, which lead to protective effects of the p allele in men. 42 However, in women, the low estradiol levels after menopause coupled with the presence of the p allele reducing the expression of ER> receptor gene leads to worse clinical consequences in terms of cardiovascular endpoints.
There is also the potential effect of calcitriol on the expression of ER> gene expression. Many studies in human cells have shown that calcitriol down-regulates the expression of ER> gene with major impact on gene transcription. 63, 64 These studies also demonstrate a decrease in the bioresponses to estrogen with calcitriol. Although these findings were predominantly found in breast cancer models, they could occur in other tissues also. The results of our study support these findings by showing a more favorable response in serum lipids to HT and calcitriol in women with the p allele as compared with the P allele. In women with the p allele, the ER> receptor gene is already underexpressed, and calcitriol has little effect on its expression. Treatment with HT, in fact, leads to better response in serum lipids as is found in men. 42 There are some limitations in our study. This is a relatively small sample size for comparing the effects of ER SNPs on serum lipids, although it is still one of the largest studies reporting the effect of interaction between ER> SNPs and HT on serum lipids. Moreover, the genotypes were analyzed by restriction endonuclease digestion and not by TaqMan probes that are more accurate.
CONCLUSIONS
ET with or without progesterone had a favorable effect on lipid profile in postmenopausal women. This was dependent on estrogen receptor alpha SNPs. Although the findings of this study are in older postmenopausal women, if applicable to younger postmenopausal women, these findings could partially explain the cardioprotective effect of estrogen when started early after menopause. The results of this study, especially the genotype analysis, are preliminary in nature, and further large trials need to be carried out to confirm our findings in both younger and older postmenopausal women and also the overall impact on event rate of MI and other outcomes.
